[Epidermal growth factor receptor in human breast cancer: correlation with steroid receptors, tumor stage, grading and menopausal status]. 1992

P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
Abteilung für Molekulare Onkologie, I. Universitäts-Frauenklinik, Wien.

In this study, correlations between the epidermal growth factor receptor (EGF-R), steroid receptors, and other prognostic parameters (grading, pTNM-status, menopausal status) were analysed in 326 primary breast carcinomas. 19% of the tumour samples were EGF-R positive, 63% were estrogen receptor (ER) and 54% progesteron receptor (PR) positive. Both steroid receptors were positive in 46% of all samples. We found a highly significant inverse correlation between EGF-R and steroid receptors. 88% of the ER positive tumours were EGF-R negative (p less than 5 x 10(-5)), 90% of the PR positive tumours were EGF-R negative (p less than 5 x 10(-5)) and 91% of the ER plus PR positive tumours were ERF-R negative (p less than 1 x 10(-6)). Grading was available in 170 cases. Six (4%) of the carcinomas were highly differentiated (G1), 82 (48%) were classified as G2, and another 82 (48%) were poorly differentiated (G3). A combination of negative ER and positive EGF-R was found more often in the population of G3 tumours. EGF-R was also positively correlated to tumour size. With regard to receptor status, we did not find a correlation with lymph node involvement. The ER correlated negatively (p less than 1.3 x 10(-5) and the EGF-R positively (p less than 0.042) with menopausal status. Thus, EGF-R overexpression seems to be a marker of morphological and functional dedifferentiation which is associated with a loss of steroid dependency and an increase of an autostimulatory-paracrine growth control. These changes seem to be related to poor prognosis.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009376 Neoplasms, Hormone-Dependent Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment. Hormone-Dependent Neoplasms,Hormone Dependent Neoplasms,Hormone-Dependent Neoplasm,Neoplasm, Hormone-Dependent,Neoplasms, Hormone Dependent
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001940 Breast In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES. Breasts
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast

Related Publications

P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
November 1988, European journal of cancer & clinical oncology,
P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
January 1995, The International journal of biological markers,
P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
December 2015, World journal of clinical oncology,
P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
January 1988, Oncology,
P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
May 1988, Breast cancer research and treatment,
P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
March 1990, European journal of cancer (Oxford, England : 1990),
P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
January 1989, Oncogene,
P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
January 1996, Acta oncologica (Stockholm, Sweden),
P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
January 1988, Cancer treatment and research,
P Speiser, and G Sliutz, and R Zeillinger, and K Czerwenka, and R Jakesz, and W Knogler, and F Kury, and A Reiner, and P Sevelda, and C Schneeberger
January 1984, Breast cancer research and treatment,
Copied contents to your clipboard!